Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.39 |
| ▸ | PPARD | Q03181 | 11/20 | 0.38 |
| ▸ | PPARA | Q07869 | 10/20 | 0.38 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6275284 | 0.86 | NPC1 (0.43) | NPC1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL4473232 | 0.85 | NPC1 (0.50) | NPC1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL4472840 | 0.82 | NPC1 (0.43) | NPC1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL2465847 | 0.81 | MAPT (0.43) | NPC1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL4462776 | 0.79 | NPC1 (0.43) | NPC1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL6221366 | 0.78 | FFAR1 (0.45) | NPC1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL6221150 | 0.77 | NPC1 (0.46) | NPC1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL4466376 | 0.75 | ALDH1A1 (0.53) | NPC1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL4475694 | 0.75 | ALDH1A1 (0.53) | NPC1ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL6221868 | 0.75 | NPC1 (0.52) | NPC1ALDH1A1GAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1480640-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1480640-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7153878-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | ELILILLY AND COMPANY | 2005-05-19 | — | — | US | disclosed |
| EP-1480640-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003072100-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | NPC1 862/4885ALDH1A1 1181/4885GAA 2159/4885 |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | NPC1 613/4885ALDH1A1 1311/4885GAA 3123/4885 |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | NPC1 638/4885ALDH1A1 1182/4885GAA 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.